2005
Guidance on the use of miglustat for treating patients with type 1 Gaucher disease
Weinreb NJ, Barranger JA, Charrow J, Grabowski GA, Mankin HJ, Mistry P. Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. American Journal Of Hematology 2005, 80: 223-229. PMID: 16247743, DOI: 10.1002/ajh.20504.Peer-Reviewed Original ResearchConceptsType 1 Gaucher diseaseEnzyme replacementGaucher diseaseSymptomatic patientsClinical manifestationsUse of miglustatProgressive lysosomal storage disorderHealth-related qualitySignificant side effectsIntravenous enzyme replacementAutosomal recessive deficiencyImiglucerase treatmentPulmonary manifestationsLysosomal storage disorderOral treatmentPulmonary diseasePatient managementSide effectsPatientsMiglustatLimited indicationsBeneficial effectsRecessive deficiencyPosition statementStorage disorder
1999
MYCOPHENOLATE MOFETIL MONOTHERAPY IN STABLE LIVER TRANSPLANT PATIENTS WITH CYCLOSPORINE-INDUCED RENAL IMPAIRMENT
Papatheodoridis G, O'Beirne J, Mistry P, Davidson B, Rolles K, Burroughs A. MYCOPHENOLATE MOFETIL MONOTHERAPY IN STABLE LIVER TRANSPLANT PATIENTS WITH CYCLOSPORINE-INDUCED RENAL IMPAIRMENT. Transplantation 1999, 68: 155-157. PMID: 10428285, DOI: 10.1097/00007890-199907150-00029.Peer-Reviewed Original ResearchConceptsStable liver transplant patientsLiver transplant patientsMajor side effectsTransplant patientsRenal impairmentMycophenolate mofetilSide effectsMycophenolate mofetil monotherapyReduction of cyclosporineSerum creatinine levelsEfficacy of monotherapyCellular rejectionIntravenous courseMaintenance immunosuppressantsMofetil monotherapyMycophenolate monotherapyCreatinine levelsSubtherapeutic levelsMonotherapyPatientsSignificant riskMonthsImpairmentMofetilCyclosporine